VYCOR MEDICAL INC (VYCO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 496,353 | 436,378 | 390,852 | 406,278 |
| Cost of goods sold | 81,082 | 77,844 | 36,796 | 35,163 |
| Gross profit | 415,271 | 358,534 | 354,056 | 371,115 |
| Selling, general and administrative | 345,043 | 350,698 | 367,886 | 337,793 |
| Research and development | 4,201 | 5,762 | 6,425 | 2,263 |
| Depreciation and amortization | 14,881 | 14,880 | 14,880 | 14,881 |
| Total operating expenses | 364,125 | 371,340 | 389,191 | 354,937 |
| Operating income | 51,146 | -12,806 | -35,135 | 16,178 |
| Interest expense, nonoperating | - | - | 12,571 | 12,841 |
| Other income | - | - | 1,458 | - |
| Interest expense-Related Party | 12,572 | - | - | - |
| Interest expense-Nonrelated Party | 12,862 | - | - | - |
| Gain (loss) on foreign currency exchange | 1 | - | -103 | 1 |
| Total other income (expense) | -25,433 | -25,708 | -24,635 | -26,167 |
| Income (loss) before provision for income taxes | 25,713 | -38,514 | -59,770 | -9,989 |
| Provision for income taxes | - | - | - | - |
| Net income (loss) from continuing operations | 25,713 | -38,514 | -59,770 | -9,989 |
| Loss from discontinued operations, net of tax | -1,826 | -49 | -47 | -49 |
| Net income (loss) | 23,887 | -38,563 | -59,817 | -10,038 |
| Preferred stock dividends | - | 162,185 | 162,185 | - |
| Net income (loss) available to common stockholders | 23,887 | -200,748 | -222,002 | -10,038 |
| Income loss available to common stockholders - basic | - | -0.01 | -0.01 | - |
| Income loss available to common stockholders - diluted | - | -0.01 | -0.01 | - |
| Weighted average number of shares outstanding basic | 33,372,796 | 33,372,796 | 32,903,493 | 32,628,835 |
| Weighted average number of shares outstanding diluted | 38,667,862 | 33,372,796 | - | 32,628,835 |